BMY Free Cash Flow Yield 2026: $12B FCF, Patent Cliff & Valuation

FCF Performance Summary

*Revenue estimated at ~$48.1B for FY2025. FCF Yield and P/FCF based on March 2026 market data.

FCF Quality Score: 8/10

Bristol-Myers Squibb has generated $12–15B in annual FCF consistently across five years, a range that reflects both the strength of the post-Celgene portfolio and the pressure from Revlimid's loss of exclusivity. The OCF/Net Income ratio of 201% is explained by the heavy amortization of Celgene acquisition intangibles, not by deteriorating fundamentals: cash earnings are real and durable. CapEx runs at just 9.3% of OCF ($1.31B on $14.16B OCF in FY 2025), which is modest for a company at this revenue scale and preserves high FCF conversion. SBC at $0.55B (3.9% of OCF) is among the lowest dilution rates in large-cap biopharma.

5-Year FCF Trend Analysis

Free Cash Flow Trajectory

FY 2021: $15.23B ──┐ ← Post-Celgene FCF peak (Revlimid fully ramped)
FY 2022: $11.95B   │ ← Revlimid generic entry begins (LOE impact)
FY 2023: $12.65B   │ ← Stabilization; new launches gain traction
FY 2024: $13.94B   │ ← Recovery; pipeline contributors growing
FY 2025: $12.85B ──┘ ← Continued moderation; patent headwinds persist

BMY's free cash flow declined from its post-acquisition peak, partially recovered in FY2024, and then moderated again in FY2025. The FY2021 peak of $15.23B, at a 32.8% margin, represented the high-water mark of Celgene integration: Revlimid was at peak revenue, Opdivo was still growing, and generic competition was minimal. That peak set the bar every subsequent year would be measured against.

The steepest single-year drop came in FY2022, when FCF fell to $11.95B as Revlimid lost patent exclusivity in the US and Europe. Generic entry rapidly eroded a drug that had generated roughly $12–13B in annual net sales at its peak, one of the best-selling oncology therapies in the world. FCF stabilized and partially recovered over FY2023–2024 as newer growth drivers, Breyanzi (CAR-T therapy), Camzyos (hypertrophic cardiomyopathy), and Sotyktu (psoriasis), began contributing meaningfully to revenue and offsetting some of the Revlimid loss. FY2025's renewed moderation to $12.85B reflects Opdivo and Eliquis patent exposure timelines starting to weigh on forward sentiment, even though current cash generation remains substantial.

The resulting 5-year FCF CAGR of -4.2% is negative, but it captures the magnitude of the Revlimid genericization rather than any broader deterioration in business quality. The 3-year average FCF for FY2023–2025, at $13.15B, understates BMY's peak earnings power but is a more useful approximation of the current run rate.

Operating Cash Flow Trend

Capital Expenditures: DISCIPLINED AND RISING MODESTLY

BMY maintains one of the lowest CapEx intensities among large-cap biopharmaceuticals: 9.3% of OCF and 2.7% of revenue in FY2025. That's a function of the asset-light nature of a patent-protected drug portfolio, where R&D (expensed through the income statement rather than capitalized) is the primary growth investment, not manufacturing equipment. Absolute CapEx has still climbed, growing 35% from $0.97B in FY2021 to $1.31B in FY2025, as BMY invests in manufacturing capacity for cell therapy (Breyanzi), biologics, and specialty pharmaceuticals. Even with that increase, the FCF conversion rate stayed high: $12.85B of FCF against $14.16B of OCF works out to 90.7% conversion, confirming that BMY turns operating cash flow into free cash flow with minimal leakage.

Cash Flow Components Deep Dive

The Celgene Amortization Story: Why OCF is 201% of Net Income

FCF Quality Indicators

The 201% OCF/NI ratio reflects non-cash amortization charges, not earnings manipulation or aggressive accrual accounting: the underlying cash generation is real. SBC discipline reinforces that picture. At just 3.9% of OCF, BMY's $0.55B of stock-based compensation is among the lowest in large-cap biopharma, a meaningful FCF quality signal that management isn't diluting shareholders to fund operations. Nearly all of that operating cash flow converts to free cash flow too: the 90.7% FCF conversion rate reflects BMY's asset-light, low-CapEx pharma business model. Even at its FY2022 trough ($11.95B), FCF didn't fall below $12B across the five-year period, a floor that speaks to the portfolio's resilience beyond any single drug. Investors relying solely on P/E ratios will systematically underestimate that cash generation; a P/FCF of 9.5x at a 10.6% FCF yield gives a more accurate valuation lens than GAAP-based metrics alone.

Comparing BMY's OCF/NI Ratio in Context

Bristol-Myers Squibb is not unique in carrying high OCF/NI ratios post-acquisition. This pattern is well-documented across the pharmaceutical sector when companies make large intangible-heavy acquisitions. Our analysis of Merck's FCF profile shows a comparable dynamic from the Prometheus Biosciences and Acceleron acquisitions. The critical distinction for FCF analysis is whether the high OCF/NI ratio reflects: (a) genuine non-cash accounting adjustments (good), or (b) aggressive accrual reversals masking underlying cash deterioration (a red flag in FCF analysis). BMY's case is clearly the former.

Capital Allocation: Dividend-Heavy Return Framework

Dividend Sustainability Analysis

Dividend Coverage: BMY paid $5.04B in dividends against $12.85B of FCF, a 39.2% FCF payout ratio. This is a conservatively covered dividend with substantial headroom. Even if FCF deteriorated 50% from current levels (an extreme scenario), the dividend would still be technically covered. For investors focused on dividend sustainability, this ratio is one of the stronger signals of safety in large-cap pharma.

That 39.2% payout ratio holds up well against peers: it's one of the more conservative FCF-based dividend ratios in large-cap healthcare. (See our analysis of how FCF yield informs dividend investing for why FCF-based payout ratios are more reliable than earnings-based ones.) Buybacks, by contrast, were absent entirely in FY2025. That signals management is prioritizing balance sheet repair and pipeline investment over shareholder returns through repurchases, consistent with the sizable debt load left by the Celgene acquisition and by recent bolt-on deals (Karuna Therapeutics for $14B, RayzeBio for $4.1B). The $7.81B of FCF retained after dividends gives BMY real flexibility, whether for pipeline-building acquisitions, debt paydown, or a future return to buybacks. M&A looks like the primary growth vector for now: with Revlimid genericized and Eliquis/Opdivo facing future patent exposure, BMY is deploying FCF into acquisitions aimed at the next generation of blockbuster drugs, and the Karuna (neuroscience/schizophrenia, KarXT) and RayzeBio (targeted radiopharmaceuticals) deals are the largest of these recent capital deployments.

FCF Quality Score: 8/10 (High Quality)

Scale, Discipline, and a Well-Covered Dividend

The scale and consistency of the FCF generation stand out first: $12–15B annually over five years is a range most companies never approach even at their peak, and the FY2023–2025 average of $13.15B represents a durable, large-scale cash floor built on multiple blockbuster drug franchises. That scale comes with unusually low dilution. SBC of $0.55B, just 3.9% of OCF, is minimal relative to the cash BMY generates, a quality signal that management isn't masking operational weakness by issuing equity at shareholders' expense; many growth biotechs run SBC at 20–40% of OCF by comparison. The FCF margin tells a similar story: at 26.7% in FY2025, even in a year with real patent headwinds, BMY generates over one dollar of free cash flow for every four dollars of revenue, a margin that reflects the pricing power of approved blockbuster drugs and the absence of commodity-like manufacturing costs.

None of this comes at the expense of transparency. Rather than a red flag, the 201% OCF/NI ratio confirms that GAAP accounting is conservatively understating BMY's true cash generation, and the cash earnings behind it are auditable in SEC filings. That cash supports a dividend that is deeply covered: the $5.04B annual payout, at a 39.2% FCF payout ratio, is one of the more conservatively structured dividends in large-cap healthcare, with a multi-year cushion even under adverse scenarios. And the capital efficiency extends to CapEx itself. At 2.7% of revenue, BMY's spending puts it among the most capital-efficient businesses in existence, since once a drug is approved and manufacturing is established, incremental revenue requires very little further capital.

The Trend, the Buybacks, and the Debt Load

Set against those strengths, the 5-year FCF CAGR is negative at -4.2%, unusual for a high-quality FCF score. The $2.38B FCF decline from the $15.23B FY2021 peak to $12.85B in FY2025 traces directly to one drug's loss of exclusivity, a concentration risk that comes with any pharmaceutical portfolio built around a handful of blockbusters. Buybacks were absent in FY2025 too: zero repurchases limit total shareholder return and may reflect balance sheet constraints tied to recent acquisitions, and investors focused on per-share FCF growth will note that share count isn't shrinking despite strong absolute FCF. That connects to the debt picture. The $74B Celgene deal, plus subsequent bolt-on acquisitions, has left BMY carrying a sizable debt load, and while debt service is manageable against $12–15B of FCF, it still limits financial flexibility and represents an ongoing claim on cash flow.

Eliquis, Opdivo, and the Pipeline Bet

Eliquis is BMY's largest revenue contributor alongside Opdivo, and its patent cliff is the next major FCF headwind. Loss of US exclusivity is expected around 2026–2028, depending on pediatric extensions and litigation outcomes; Eliquis generated roughly $12B in global net sales at its peak (shared with Pfizer), and BMY's share represents a substantial fraction of current revenue. Opdivo carries its own risk. The flagship immuno-oncology drug faces intensifying competition from Keytruda (Merck's pembrolizumab) across multiple indications, and its patent protection expires in the late 2020s, adding another layer of potential revenue erosion.

The recovery thesis rests heavily on execution elsewhere. BMY's newer drugs, Breyanzi, Camzyos, Sotyktu, and the Karuna/RayzeBio pipeline, need to reach meaningful scale, and drug development carries inherent clinical and regulatory risk: if key pipeline assets fail to reach forecast revenue, forward FCF would come under real pressure. The $14B Karuna and $4.1B RayzeBio deals add further complexity to an already intricate post-Celgene integration, and large acquisitions like these have historically created transient FCF drag and management distraction. Layered on top is drug pricing policy: the Inflation Reduction Act's Medicare drug pricing negotiation provisions are a new structural headwind for large-pharma FCF, and both Eliquis and Opdivo have been subject to government negotiation processes, with price reductions scheduled to take effect 2026–2028.

Forward Outlook & Scenario Analysis

Key Catalysts to Monitor

A handful of catalysts will determine which of these scenarios plays out. Eliquis litigation outcomes matter most immediately: BMY and Pfizer have been defending Eliquis patents against generic challengers, and the timing and outcome of Paragraph IV litigation will determine the actual onset of generic competition, a multi-billion-dollar FCF binary event on its own. The KarXT (Cobenfy) launch trajectory is the clearest upside lever. Acquired through the $14B Karuna deal, KarXT is an FDA-approved schizophrenia treatment with a novel mechanism of action, and analyst peak sales estimates range from $2B to $5B or more annually; successful commercial scaling would be the single most important positive FCF catalyst available to BMY. Breyanzi, Camzyos, and Sotyktu carry sizable market opportunities of their own across hematology, cardiovascular, and dermatology, and accelerating revenue from the three combined could offset a real portion of the Eliquis/Opdivo LOE impact.

On the policy side, the Medicare Drug Price Negotiation Schedule is worth tracking closely: Eliquis is among the drugs targeted for Medicare price negotiation under the IRA, and the effective negotiated price and implementation timeline will set the floor for BMY's Eliquis FCF contribution after 2026. As the first round of IRA price negotiation impacts rolls through in 2026, investors will finally be able to quantify the actual versus estimated FCF headwind, a catalyst that could cut either direction depending on whether outcomes land better or worse than consensus. Underneath all of this sits a capital-allocation question: how management balances paying down Celgene-era debt, which is FCF-positive over the long term, against continuing to deploy capital into acquisitions, which creates short-term FCF drag, will shape the trajectory of net FCF available to shareholders.

Conclusion

Bristol-Myers Squibb demonstrates high-quality FCF characteristics anchored by $12.85B in FY2025 free cash flow, a 26.7% FCF margin, a 201% OCF/NI conversion ratio reflecting the economic reality of Celgene acquisition amortization, and an exceptionally low SBC dilution profile ($0.55B, 3.9% of OCF). Together, these place it among the most cash-generative and shareholder-aligned large-cap biopharmaceuticals on a pure free cash flow basis.

The key analytical insight of this analysis is the distinction between BMY's reported GAAP earnings and its true cash generation power. Net income of $7.05B in FY2025 is depressed by roughly $6.56B of non-cash amortization charges on Celgene intangibles, which dramatically understates the company's ability to generate, distribute, and deploy cash. The 201% OCF/NI ratio is the clearest expression of this dynamic: BMY is a cash machine reporting modest GAAP earnings. Investors evaluating BMY primarily through a P/E lens are looking at an incomplete picture.

The FCF trajectory from $15.23B (FY2021) to $12.85B (FY2025) tells the story of Revlimid's genericization, a $2–3B annual revenue headwind absorbed in real time by a portfolio diversified enough to keep FCF above $12B through the transition. That floor is now being tested again as the market looks toward Eliquis and Opdivo patent expirations. The $5.04B dividend, covered at a conservative 39.2% of FCF, is well-protected at current levels, though the margin of safety narrows meaningfully in the bear case scenario below $9B FCF.

The 10.6% FCF yield at a 9.5x P/FCF multiple reflects the market's skepticism about forward FCF sustainability, a rational discount given the patent cliff ahead. Whether that discount is excessive or appropriate depends primarily on the commercial success of KarXT, the pace of Eliquis genericization, and the IRA pricing impact quantification. These are knowable variables with defined timelines, making BMY's FCF trajectory unusually analyzable relative to earlier-stage pharmaceutical businesses. The framework for assessing whether this yield level is attractive or appropriately valued is well-captured in our analysis of what constitutes a good FCF yield across different risk profiles.

Disclaimer: This analysis is for educational and informational purposes only and does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. The information presented here is based on publicly available data and is provided for analytical and educational purposes. You should not make any investment decision based solely on this analysis. Always conduct your own independent due diligence and consult with a licensed financial advisor before making any investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Pharmaceutical investments carry additional risks including clinical trial failure, regulatory rejection, patent litigation outcomes, and competitive dynamics that may differ materially from historical patterns.

Data Sources: SEC Edgar XBRL filings, Stock Analysis (stockanalysis.com), Bristol-Myers Squibb FY2021–FY2025 Annual Reports (10-K filings)
Methodology: Direct extraction from annual cash flow statements; FCF calculated as Operating Cash Flow minus Capital Expenditures; 5-year averages calculated from FY2021–FY2025 data; revenue estimates derived from company-reported figures